Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.
about
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonistClinical trials of glycoprotein IIb/IIIa inhibitorsFatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment.Platelet kinetics in dogs treated with a glycoprotein IIb/IIIa peptide antagonist.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.A case report of alveolar haemorrhage associated with severe thrombocytopenia induced by abciximab infusion in a patient with an acute coronary syndrome.The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus IntracoronaryThe evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.Cystine-knot peptides engineered with specificities for α(IIb)β(3) or α(IIb)β(3) and α(v)β(3) integrins are potent inhibitors of platelet aggregation.Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients.Platelet glycoprotein receptor site blockade in coronary artery disease.Bleeding complications associated with glycoprotein IIb/IIIa inhibitors in patients 80 years of age and older undergoing percutaneous coronary interventionThe effects of platelet inhibitors on blood use in cardiac surgery.The use of the glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary intervention.Noncoronary complications of coronary intervention.Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy.Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplastyGlycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary.Platelet glycoprotein IIb/IIIa polymorphism HPA-3 b/b is associated with increased risk of ischemic stroke in patients under 60 years of age.Issues in management of acute coronary syndromes: effects of bleeding.Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk.Remote suturing for percutaneous closure of popliteal artery access.Salvianolic acid A protects against myocardial ischemia/reperfusion injury by reducing platelet activation and inflammation.Clinical trials to prevent restenosis after percutaneous coronary revascularization.A Case of Diffuse Alveolar Hemorrhage as a Possible Complication of Bivalirudin Therapy.Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors.Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes.Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.Failure of enoxaparin during coronary stenting: a case report.Fatal alveolar hemorrhage and Abciximab (ReoPro) therapy for acute myocardial infarction.Impact of age on the outcomes of women following percutaneous coronary intervention in the bare-metal stent era.Randomized comparison of effects of suture-based and collagen-based vascular closure devices on post-procedural leg perfusion.A randomised controlled trial comparing the routine use of an Angio-Seal STS device strategy with conventional femoral haemostasis methods in a district general hospital.Association of the antagonism of von Willebrand factor but not fibrinogen by platelet alphaIIbbeta3 antagonists with prolongation of bleeding time.Vascular access site complications with the use of closure devices in patients treated with platelet glycoprotein IIb/IIIa inhibitors during rescue angioplasty.Technological advances in the design of catheters and devices used in renal artery interventions: impact on complications.
P2860
Q28181764-8A836F59-B328-4E78-94BB-958027A754F3Q28193162-A602D551-D72E-4DBD-B59E-8833663AB634Q33331255-D89C5380-3C69-4BDF-B0F2-AEF3C327F50EQ33332409-65F92186-9C3D-484A-80A9-25261DE7B281Q33365571-E522A693-4C46-4847-8C81-6335B2795CC2Q33367036-C73C02CF-3A4D-4DDE-85D4-426B69AA8363Q33380071-64996645-3564-4002-BE41-BB04E6BDD62CQ33572281-6C351084-163D-4969-9BFE-4E87E20B4231Q33689211-0C2D7CC4-30D5-4A0A-B995-A85CC77C7DB6Q33782671-3E338ACA-2AD7-47F6-947A-17C3FC60D81CQ33914229-24002015-B42E-4CA8-9012-0324B70C29F4Q34027408-3680409A-4E59-4C6B-9DCF-64A64A8DD8D3Q34194271-F7543316-F3AA-4728-B0BA-0A57D97DCA32Q34510678-E23143BD-6F6F-4C31-8112-D57DFD888B7DQ34675290-F4FF9800-39B7-422D-8C15-4F7D2C2DA36FQ34926982-10E83204-E287-4ABE-8F15-7A4D2F263A22Q35026617-A111D159-C7AA-462D-A92D-4F108CE9A7E2Q35663845-91FA0901-966D-48A9-8EDB-DF877C10D65AQ35820037-DFABEF8D-ACF9-4227-91D8-3CFC1EC450B7Q35924051-8F0A5870-B862-4400-94B3-96911DC84DAEQ36179701-2831A150-3F55-4F33-9890-ABADAEBFB2A8Q36577161-7B6F074C-6FA5-4CC6-86D9-46DA215577FAQ37070767-B480658B-6C38-4EF8-95BE-E67AE66F693EQ37070782-07933C11-1A91-41D6-B80E-F9B4F88FA1FAQ39465215-EA0BBFDC-0F93-4169-B3A1-F85C3B6C53D4Q41116679-7DB5D629-687B-4398-8D0A-08338F8F0A2CQ41500665-1F787008-8FE3-45F8-9901-69CF07D3B22EQ42379392-83E895A3-C960-48AA-8DC6-EE4EE1476DBAQ44237134-63BFB560-6401-4DEA-B0C5-4DE1D19B434AQ44267032-6F81558B-8298-4F89-B1A8-052D63B52618Q44321710-EB89984A-5CBB-42E7-B720-5DC3A7AE7D86Q44455330-A3DD51FF-105E-4650-A63E-D84ED6C2CE81Q46697513-038A3C5D-6E5F-44B8-AC51-DCBFDED299CDQ47794624-18555400-ECBC-44B5-9C63-CFEEF24C60B9Q50110538-CAC1242D-AA74-4C97-B9A6-FFB79AD87B67Q50910557-0EBFBA0F-7297-48CC-83E2-0D915BC9EAA8Q51062998-EB708FD6-3273-4AD3-A845-8544835AAB0BQ51358552-AFDA7FE0-408B-464F-93DC-8978518A29A9Q51593770-0FDA87F9-C135-49A4-AB9D-588E2D216CAAQ51789531-58E11567-CC12-4019-9F68-D5B966F40CD3
P2860
Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Bleeding complications with th ...... ervention. EPIC Investigators.
@en
type
label
Bleeding complications with th ...... ervention. EPIC Investigators.
@en
prefLabel
Bleeding complications with th ...... ervention. EPIC Investigators.
@en
P2093
P1433
P1476
Bleeding complications with th ...... ervention. EPIC Investigators.
@en
P2093
Aguirre FV
Anderson K
Blankenship JC
Ferguson JJ
Gottlieb R
Hanovich G
P304
P356
10.1161/01.CIR.91.12.2882
P407
P50
P577
1995-06-01T00:00:00Z